Pharming Grp Nv Leid (PHGUF) 0.2750 $PHGUF
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire Europe - Thu Oct 08, 12:01AM CDT
LEIDEN, Netherlands and BRIDGEWATER, New Jersey, October 8, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 7.58 (+0.71)
Pharming to elect Robin Wright as CFO at EGM
M2 - Tue Sep 08, 3:02AM CDT
Medical products company Pharming Group NV (Amsterdam
HARM.AS) reported on Tuesday that it plans to elect Robin Wright as its new chief financial officer (CFO) and member of the management board at an Extraordinary General Meeting (EGM) of shareholders to be held on 28 October 2015 at 14:00 CET.
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 100.65 (-0.16), OMER: 12.66 (+0.58)
Hemophilia A Pipeline Review, H1 2015 - 32 Companies & 39 Drug Profiles
M2 - Fri Jul 31, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rdjwhc/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - Novo Nordisk A/S - Octapharma AG - OPKO Health, Inc. - Pharming Group N.V. - Promethera Biosciences S.A. - rEVO Biologics - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/rd...mophilia_a
NVO: 54.61 (-0.12), BMRN: 102.69 (+1.97), EBS: 30.49 (+0.77), OPK: 8.90 (+0.26), ONCE: 49.30 (+1.86), AZN: 32.23 (-0.16), SGMO: 5.94 (+0.38), RBIO: ()
Pharming Group NV signs EUR15.6m straight debt financing with Oxford Finance and Silicon Valley Bank
M2 - Mon Jul 20, 6:20AM CDT
Biotech company Pharming Group NV (Amsterdam HARM.AS) reported on Friday the execution of a EUR15.6m straight debt financing with Oxford Finance and Silicon Valley Bank (the lenders).
Kidney Transplantation Pipeline Review, H1 2015 - 20 Companies & 28 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkfdjl/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - CSL Limited - Digna Biotech, S.L. - Effimune SAS - GlaxoSmithKline plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Ltd. - Pharmicell Co., Ltd. - Pharming Group N.V. - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tolera Therapeutics, Inc. Drug Profiles - albumin (human) - AS-2521780 - ASKP-1240 - BB-3 - belimumab - BRN-1889 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - cardiotrophin-1 - carfilzomib - Cell Therapy for Kidney Transplantation - Cell Therapy for Kidney Transplantation - CFZ-533 - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FX-06 - IgG-Degrading Enzyme of Streptococcus pyogenes - Immucellgram - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - TOL-101 - voclosporin For more information visit http://www.researchandmarkets.com/research/fkfdjl/kidney
SHPG: 200.90 (-1.85), ALXN: 161.08 (-3.23), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Hereditary Angioedema (HAE) Therapeutics Pipeline Review, H1 2015 - 10 Companies & 13 Drug Profiles
M2 - Thu Jul 09, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fc274/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - Ra Pharmaceuticals, Inc. - Shire Plc Drug Profiles - BCX-4161 - BCX-7353 - BEL-0215 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - CSL-312 - DX-2930 - icatibant acetate - ISIS-PKKRx - Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Small Molecule for Hereditary Angioedema - Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema For more information visit http://www.researchandmarkets.com/research/7fc274/hereditary
BCRX: 8.80 (-0.95), ISIS: 43.24 (+0.86), SHPG: 200.90 (-1.85), IBIO: 0.68 (unch), DYAX: 24.00 (+1.64)
Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles
M2 - Thu Jul 09, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndp4wj/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca PLC - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pharming Group N.V. - rEVO Biologics - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - nonacog alfa biosimilar - nonacog beta pegol - PF-05280602 - Recombinant Enzyme to Replace Factor IX for Hemophilia B - SHP-624 - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/nd...mophilia_b
NVO: 54.61 (-0.12), EBS: 30.49 (+0.77), OPK: 8.90 (+0.26), ONCE: 49.30 (+1.86), AZN: 32.23 (-0.16), SGMO: 5.94 (+0.38), RBIO: ()
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 102.69 (+1.97), SRPT: 37.09 (-0.72), FOLD: 7.58 (+0.71)
Fabry Disease Pipeline Review, H1 2015 Edition
M2 - Thu Jun 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9l8prv/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - Synageva BioPharma Corp. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Alpha-Galactosidase - Genz-682452 - GZ-402671 - JR-051 - migalastat hydrochloride - Next Generation biologics for Pompe, Fabry and Hunter - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease For more information visit http://www.researchandmarkets.com/research/9l...ry_disease
GEVA: 238.60 (+2.80), IBIO: 0.68 (unch), FOLD: 7.58 (+0.71)
Pharming to distribute Ruconest through Cytobioteck for treating HAE in Colombia and Venezuela
M2 - Tue May 26, 3:00AM CDT
Medical company Pharming Group NV (Amsterdam HARM.AS) revealed on Monday the launch of an exclusive distribution agreement for the distribution of RUCONEST (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in Colombia and Venezuela.
Pharming and Cytobioteck Announce Distribution Agreement for Ruconest
PR Newswire Europe - Mon May 25, 12:01AM CDT
LEIDEN, The Netherlands, May 25, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming Reports on Annual General Meeting of Shareholders
PR Newswire Europe - Thu Apr 30, 11:34AM CDT
LEIDEN, The Netherlands, April 30, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming Reports on Financial Results for Q1 2015
PR Newswire Europe - Thu Apr 30, 12:01AM CDT
LEIDEN, The Netherlands, April 30, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming nominates two new members to board of supervisory directors
M2 - Fri Mar 20, 5:49AM CDT
Medical company Pharming Group NV (Amsterdam HARM.AS) revealed on Thursday that Paul Jai Sekhri and Jan Hendrik Egberts have been nominated to its board of supervisory directors.
Pharming Nominates Paul Sekhri and Jan Egberts as Members of its Board of Supervisory Directors
PR Newswire Europe - Thu Mar 19, 1:01AM CDT
LEIDEN, The Netherlands, March 19, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming Group: Amid Current Bidding War For Salix, Everything Seems Fine For Ruconest And U.S. Sales
Logribel Biostocks - at Seeking Alpha - Fri Mar 13, 9:49AM CDT
ENDP: 64.27 (+0.85), VRX: 175.94 (+4.77), SHPG: 200.90 (-1.85), SLXP: 172.96 (+0.15)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 175.94 (+4.77), SLXP: 172.96 (+0.15), ICPT: 181.90 (-8.81), SPPI: 6.20 (+0.07), EXAS: 8.51 (+0.71)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 269.16 (-10.72), BMRN: 102.69 (+1.97), CVM: 0.72 (-0.02), MDGN: 7.21 (+0.08), PFE: 33.24 (+0.15), SGMO: 5.94 (+0.38), RPRX: 7.81 (+0.05), MNKD: 3.05 (+0.04), CELG: 117.38 (-0.59), SGEN: 39.38 (+0.87), TEVA: 58.96 (-0.28), ARIA: 7.02 (+0.21), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire Europe - Thu Oct 08, 12:01AM CDT
LEIDEN, Netherlands and BRIDGEWATER, New Jersey, October 8, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 7.58 (+0.71)
Pharming to elect Robin Wright as CFO at EGM
M2 - Tue Sep 08, 3:02AM CDT
Medical products company Pharming Group NV (Amsterdam
HARM.AS) reported on Tuesday that it plans to elect Robin Wright as its new chief financial officer (CFO) and member of the management board at an Extraordinary General Meeting (EGM) of shareholders to be held on 28 October 2015 at 14:00 CET. Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 100.65 (-0.16), OMER: 12.66 (+0.58)
Hemophilia A Pipeline Review, H1 2015 - 32 Companies & 39 Drug Profiles
M2 - Fri Jul 31, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rdjwhc/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - Novo Nordisk A/S - Octapharma AG - OPKO Health, Inc. - Pharming Group N.V. - Promethera Biosciences S.A. - rEVO Biologics - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/rd...mophilia_a
NVO: 54.61 (-0.12), BMRN: 102.69 (+1.97), EBS: 30.49 (+0.77), OPK: 8.90 (+0.26), ONCE: 49.30 (+1.86), AZN: 32.23 (-0.16), SGMO: 5.94 (+0.38), RBIO: ()
Pharming Group NV signs EUR15.6m straight debt financing with Oxford Finance and Silicon Valley Bank
M2 - Mon Jul 20, 6:20AM CDT
Biotech company Pharming Group NV (Amsterdam
HARM.AS) reported on Friday the execution of a EUR15.6m straight debt financing with Oxford Finance and Silicon Valley Bank (the lenders). Kidney Transplantation Pipeline Review, H1 2015 - 20 Companies & 28 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkfdjl/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - CSL Limited - Digna Biotech, S.L. - Effimune SAS - GlaxoSmithKline plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Ltd. - Pharmicell Co., Ltd. - Pharming Group N.V. - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tolera Therapeutics, Inc. Drug Profiles - albumin (human) - AS-2521780 - ASKP-1240 - BB-3 - belimumab - BRN-1889 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - cardiotrophin-1 - carfilzomib - Cell Therapy for Kidney Transplantation - Cell Therapy for Kidney Transplantation - CFZ-533 - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FX-06 - IgG-Degrading Enzyme of Streptococcus pyogenes - Immucellgram - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - TOL-101 - voclosporin For more information visit http://www.researchandmarkets.com/research/fkfdjl/kidney
SHPG: 200.90 (-1.85), ALXN: 161.08 (-3.23), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Hereditary Angioedema (HAE) Therapeutics Pipeline Review, H1 2015 - 10 Companies & 13 Drug Profiles
M2 - Thu Jul 09, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fc274/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - Ra Pharmaceuticals, Inc. - Shire Plc Drug Profiles - BCX-4161 - BCX-7353 - BEL-0215 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - CSL-312 - DX-2930 - icatibant acetate - ISIS-PKKRx - Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Small Molecule for Hereditary Angioedema - Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema For more information visit http://www.researchandmarkets.com/research/7fc274/hereditary
BCRX: 8.80 (-0.95), ISIS: 43.24 (+0.86), SHPG: 200.90 (-1.85), IBIO: 0.68 (unch), DYAX: 24.00 (+1.64)
Hemophilia B Pipeline Review, H1 2015 - 17 Companies & 24 Drug Profiles
M2 - Thu Jul 09, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndp4wj/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca PLC - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pharming Group N.V. - rEVO Biologics - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - nonacog alfa biosimilar - nonacog beta pegol - PF-05280602 - Recombinant Enzyme to Replace Factor IX for Hemophilia B - SHP-624 - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/nd...mophilia_b
NVO: 54.61 (-0.12), EBS: 30.49 (+0.77), OPK: 8.90 (+0.26), ONCE: 49.30 (+1.86), AZN: 32.23 (-0.16), SGMO: 5.94 (+0.38), RBIO: ()
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 102.69 (+1.97), SRPT: 37.09 (-0.72), FOLD: 7.58 (+0.71)
Fabry Disease Pipeline Review, H1 2015 Edition
M2 - Thu Jun 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9l8prv/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - Synageva BioPharma Corp. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Alpha-Galactosidase - Genz-682452 - GZ-402671 - JR-051 - migalastat hydrochloride - Next Generation biologics for Pompe, Fabry and Hunter - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease For more information visit http://www.researchandmarkets.com/research/9l...ry_disease
GEVA: 238.60 (+2.80), IBIO: 0.68 (unch), FOLD: 7.58 (+0.71)
Pharming to distribute Ruconest through Cytobioteck for treating HAE in Colombia and Venezuela
M2 - Tue May 26, 3:00AM CDT
Medical company Pharming Group NV (Amsterdam
HARM.AS) revealed on Monday the launch of an exclusive distribution agreement for the distribution of RUCONEST (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in Colombia and Venezuela. Pharming and Cytobioteck Announce Distribution Agreement for Ruconest
PR Newswire Europe - Mon May 25, 12:01AM CDT
LEIDEN, The Netherlands, May 25, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming Reports on Annual General Meeting of Shareholders
PR Newswire Europe - Thu Apr 30, 11:34AM CDT
LEIDEN, The Netherlands, April 30, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming Reports on Financial Results for Q1 2015
PR Newswire Europe - Thu Apr 30, 12:01AM CDT
LEIDEN, The Netherlands, April 30, 2015 /PRNewswire/ --
VRX: 175.94 (+4.77), VRX.TO: 227.56 (+4.67)
Pharming nominates two new members to board of supervisory directors
M2 - Fri Mar 20, 5:49AM CDT
Medical company Pharming Group NV (Amsterdam
HARM.AS) revealed on Thursday that Paul Jai Sekhri and Jan Hendrik Egberts have been nominated to its board of supervisory directors. Pharming Nominates Paul Sekhri and Jan Egberts as Members of its Board of Supervisory Directors
PR Newswire Europe - Thu Mar 19, 1:01AM CDT
LEIDEN, The Netherlands, March 19, 2015 /PRNewswire/ --
SLXP: 172.96 (+0.15)
Pharming Group: Amid Current Bidding War For Salix, Everything Seems Fine For Ruconest And U.S. Sales
Logribel Biostocks - at Seeking Alpha - Fri Mar 13, 9:49AM CDT
ENDP: 64.27 (+0.85), VRX: 175.94 (+4.77), SHPG: 200.90 (-1.85), SLXP: 172.96 (+0.15)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 175.94 (+4.77), SLXP: 172.96 (+0.15), ICPT: 181.90 (-8.81), SPPI: 6.20 (+0.07), EXAS: 8.51 (+0.71)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 269.16 (-10.72), BMRN: 102.69 (+1.97), CVM: 0.72 (-0.02), MDGN: 7.21 (+0.08), PFE: 33.24 (+0.15), SGMO: 5.94 (+0.38), RPRX: 7.81 (+0.05), MNKD: 3.05 (+0.04), CELG: 117.38 (-0.59), SGEN: 39.38 (+0.87), TEVA: 58.96 (-0.28), ARIA: 7.02 (+0.21), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
